SEC Form 3 · accession 0001209191-17-003808
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Santosh Vetticaden
Officer — Interim CEO
Period of report
Jan 9, 2017
Accepted (ET)
Jan 17, 2017 · 10:37 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,428 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $26.75 | holding | — | — | — | — | May 5, 2025 | Common Stock | 140,000 | — | D |
| Employee Stock Option (right to buy)F2 | $14.44 | holding | — | — | — | — | May 2, 2026 | Common Stock | 84,699 | — | D |
Explanation of responses
- F1The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 5, 2019.
- F2The option vests in 48 equal monthly installments and will be fully vested and exercisable on May 2, 2020.